Coronavirus Update: Pfizer Switches To Alternate COVID Vaccine Over T Cell Response

Plus: Yuhan and Abclon Advance Candidate

 
• By Scrip Team

Signs that BNT162b2 could be more effective in older age groups led companies to switch lead candidates, and they now head into a pivotal late-stage study.

Pfizer
Pfizer and BioNTech's Phase II/III study will be conducted across the US and countries such as Argetina, Brazil and Germany. • Source: Shutterstock

More from COVID-19

More from Scrip